

Curriculum Vitae

Name: **Natia**

Surname: **Karumidze**

Nationality: **Georgian**

Date of birth: **30 January, 1984**

Marital status: **Single**

Current address: **6 Baku Str, Tbilisi, Georgia**

Phone: **(+995 551) 00 22 02**

E-mail: natiaqarumidze@pha.ge

1. Education

| № | Years | Name of the University/Institute, Country | Academic Degree | Major / Specialty |
|---|-----------|---|-----------------|-------------------|
| 1 | 2008-2013 | Ilia State University | PhD | Microbiology |
| 2 | 2001-2006 | Tbilisi State Medical University | Master | Pharmacy |

2. Work Experience

| № | Years | Position | Department / Unit | Organization |
|---|--------------|---------------------------|----------------------------------|---|
| 1 | 2005 - today | Senior Research scientist | Lab of General Microbiology | Eliava Institute of Bacteriophages, Microbiology and Virology |
| 2 | 2015-2016 | Post-Doc | Institute of Infectious Diseases | University of Bern |
| 3 | From 2018 | Lecturer | European University | European University |

3. Participation in Research Projects (over the last 5 years)

| № | Years | Position / Responsibility | Project Title | Donor Organization |
|---|-----------|---------------------------|---|---|
| 1 | 2018-2021 | Key personnel | Creation of polyclonal immunoglobulin for treatment of complicated Staphylococcal infections | SRNSF |
| 2 | 2017-2020 | Key personnel | Constructing a 'Eubiosis Reinstatement Therapy' for Asthma | H2020-FETOPEN-2016-2017 |
| 4 | 2018 | Principal investigator | Selection of synthetic media for production of commercial phage preparation | G. Eliava Foundation |
| 5 | 2016-2017 | Key personnel | The role of XhIA domain containing protein in the development of lysogenic conversion | SRNSF |
| 6 | 2015-2016 | Principal Investigator | Phage activity against anti Clustered regularly interspaced short palindromic repeats in Gram-negative bacteria | Swiss Government Excellence Scholarship |

| | | | | |
|----|-----------|------------------------|--|--------------------------|
| 6 | 2014-2015 | Principal Investigator | Endolysins as novel class of antibacterial agents | GRDF/SRNSF |
| 7 | 2011-2015 | Key personnel | Design of Novel Portable-Sensors Based on Suspension Arrays Composed of Monoclonal Antibody and Bacteriophage Carrying Magnetically Loaded Nanoparticles and Surface Enriched Raman Spectroscopy | 7FP PIAPP-GA 2011 286468 |
| 8 | 2013 | Principal Investigator | Biofilm formation and their Inhibition with Bacteriophages | SRNSF |
| 9 | 2011-2012 | Principal Investigator | Study of Phage therapy effects on animal model of Sepsis caused by Staphylococcus aureus and Enterococcus faecalis | SRNSF |
| 10 | 2009-2010 | Principal Investigator | Characterisation of freshly isolated clones of bacteriophages against P.aeruginosa and Klebsiella for involving them into natural antimicrobial-antifungal biocomposite | GRDF/SRNSF |

4. List of Publications in the International Peer Reviewed Journals (over the last 5 years) *

| № | Publication Title | Journal title, series, volume issue (publication date): page (s) or, book / monograph title, edition #, series publisher, city, year published |
|---|---|---|
| 1 | Characterization of Lytic Pseudomonas aeruginosa Bacteriophages via Biological Properties and Genomic Sequences | Applied Microbiology and Biotechnology, Volume 94, Number 6 (2012), 1609-1617, DOI: 10.1007/s00253-012-4119-8 |
| 2 | Isolation and characterization of lytic bacteriophages of Klebsiella pneumoniae and Klebsiella oxytoca | Current Microbiology, Volume 66, Issue 3, pp 251-258, March 2013 |
| 3 | Characterization and Testing the Efficiency of Acinetobacter baumannii Phage vB-GEC_Ab-M-G7 as an Antibacterial Agent | Frontiers in Microbiology, section Antimicrobials, Resistance and Chemotherapy. Front. Microbiol., 04 October 2016 http://dx.doi.org/10.3389/fmicb.2016.01590 |
| 4 | Immobilization of bacteriophage in wound-dressing nanostructure | Nanomedicine: nanotechnology, biology and medicine. 2017 Nov;13(8):2475-2484. doi: 10.1016/j.nano.2017.08.008. Epub 2017 Aug 26. |
| 5 | New Temperate Enterococcus phage vB_GEC_EFS_2 with potential of lysogenic conversion | Georgian Medical News, January 2018 |

5. Participation in International Forums/Conferences (up to 5 events)

| № | Year | Event title | Venue | Presentation title |
|---|------|--|--------------------|--|
| 1 | 2019 | Alternative Approaches to Combatting Anti-Microbial Resistance (AMR)'' | Almaty, Kazakhstan | Activity of Commercial Bacteriophage Cocktails and E.coli Monophage towards Multidrug-Resistant E.coli Strains |
| 2 | 2017 | International conference on clinical and pharmaceutical microbiology | Rome , Italy | New temperate Enterococcus bacteriophage vB_GEC_EFS_2 with potential of lysogenic conversion |
| 3 | 2016 | SSM, Swiss Medlab 2016 | Bern, Switzerland | Susceptibility of Multidrug-Resistant <i>E. coli</i> strains to commercial bacteriophage cocktails |

| | | | | |
|---|------|--|------------------|---|
| | | | | and monophage |
| 4 | 2016 | Viruses of Microbes | Liverpool, UK | Sequence based comparative characterization of phages vB_GEC-EfS_2 and vB_GEC-EfSa_4 |
| 5 | 2015 | International Max Plank Focus Symposium | Berlin, Germany | Characterization of <i>Enterococcus</i> Bacteriophages against multi-drug resistant pathogens |
| 6 | 2015 | Boston Bacterial Meeting | Boston, USA | Characterization of Bacteriophages against multi-drug resistant pathogens |
| 7 | 2014 | 24 th European Congress of Clinical Microbiology and infectious diseases (ECCMID 2014) | Barcelona, Spain | Prospective usage of Pseudomonas phages as alternative antimicrobials. |

6. Languages

| | | | |
|---------|----------|--|--|
| English | Fluently | | |
| Russian | Good | | |
| French | Beginner | | |